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Abstract 24 
Metastatic prostate cancer is a leading cause of cancer-related death in men and current 25 
chemotherapies are largely inadequate in terms of efficacy and toxicity, hence improved 26 
treatments are required. The application of siRNA as a cancer therapeutic holds great 27 
promise. However, translation of siRNA into the clinic is dependent on the availability of an 28 
effective delivery system. Gold nanoparticles (AuNPs) are known to be effective and non-29 
toxic siRNA delivery agents. In this study, a stable gold nanosphere coated with 30 
poly(ethylenimine) (PEI) was prepared to yield PEI capped AuNPs (Au-PEI). The PEI was 31 
further conjugated with the targeting ligand anisamide (AA, is known to bind to the sigma 32 
receptor overexpressed on the surface of prostate cancer cells) to produce an anisamide-33 
targeted nanoparticle (Au-PEI-AA). The resulting untargeted and targeted nanoparticles (Au-34 
PEI and Au-PEI-AA respectively) were positively charged and efficiently complexed siRNA. 35 
Au-PEI-AA mediated siRNA uptake into PC3 prostate cancer cells via binding to the sigma 36 
receptor. In addition, the Au-PEI-AA.siRNA complexes resulted in highly efficient 37 
knockdown of the RelA gene (~ 70 %) when cells were transfected in serum-free medium. In 38 
contrast, no knockdown was observed in the presence of serum, suggesting that adsorption of 39 
serum proteins inhibits the binding of the anisamide moiety to the sigma receptor. This study 40 
provides (for the first time) proof of principle that anisamide-labelled gold nanoparticles can 41 
target the sigma receptor. Further optimisation of the formulation to increase serum stability 42 
will enhance its potential to treat prostate cancer. 43 
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1 Introduction  44 
Prostate cancer is expected to be the second-leading cause of cancer-related death in men in 45 
the US in 2015 1. Despite improvements in the treatments available for prostate cancer, 46 
particularly relating to patients who have developed metastatic ‘castrate resistant’ disease, 47 
current therapies can offer only limited increases in lifespan 2. Because of this there is an 48 
urgent need to develop improved therapies for those whose prostate cancer has developed to 49 
this stage 3. As a consequence of the increased understanding of the genetic changes within 50 
the cell which can contribute to the development and spread of prostate cancer 4, small 51 
interfering RNA (siRNA) has been investigated for the treatment of prostate cancer with very 52 
promising results 5, 6. siRNA can regulate gene expression by binding specifically to 53 
corresponding mRNA molecules. These mRNA molecules are then blocked from undergoing 54 
the normal process of translation into protein or, alternatively, are degraded in the cytoplasm 55 
7.  56 
Although siRNA has potential to treat human diseases, there are major obstacles impeding 57 
the in vivo application of such therapy 4. The major barrier to the use of siRNA therapy in the 58 
clinic is delivery 8. Naked siRNA duplexes are highly unstable, especially in the serum, 59 
demonstrate extremely low cellular uptake and transfection efficiencies, and may induce 60 
immune system activation following systemic administration9-11. Delivery systems or 61 
‘vectors’ formulated as nanoparticles have been used to protect siRNA in the circulation and 62 
to ensure cellular uptake after administration. Theoretically, following systemic 63 
nanoparticulate siRNA delivery in vivo, any cell within the body can be transfected. This may 64 
result in harmful consequences to healthy cells 12 and lead to the requirement for higher 65 
amounts of siRNA to be administered to achieve therapeutic efficacy. Therefore, the 66 
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incorporation of a targeting ligand into the delivery vector to facilitate site-specific delivery 67 
to target tissues and cells is critical for success 13. 68 
Among the range of nanoparticulate delivery vector systems under investigation are gold 69 
nanoparticles (AuNPs) which can be readily functionalised and are capable of delivering both 70 
small drug molecules and large biomolecules, such as proteins, DNA and RNA 14. The gold 71 
core can be easily modified to yield cationic AuNPs which complex siRNA via electrostatic 72 
interaction 15. The ability of cationic AuNPs to bind siRNA, protect it from enzymatic 73 
degradation and mediate gene silencing has been reported previously 16. 74 
The aim of this project was to develop an anisamide-labelled AuNP for targeted delivery of 75 
siRNA which binds to the sigma receptor that is overexpressed on the surface of prostate 76 
cancer cells. The gold was functionalised with PEI to give a cationic AuNP capable of 77 
binding siRNA (Au-PEI). To mediate specific uptake in prostate cancer cells, the PEI coating 78 
was modified with the anisamide-ligand (Au-PEI-AA). The resulting Au-PEI-AA 79 
nanoparticle was assessed for its capacity to complex siRNA, to facilitate receptor-mediated 80 
endocytosis and to silence genes in both the absence and presence of serum in sigma receptor 81 
positive PC3 prostate cancer cells. 82 
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2 Materials/Methods 83 
2.1 Reagents 84 
All materials were purchased from Sigma unless otherwise stated. Negative control non-85 
silencing siRNA (sense strand sequence 5’-UUC UCC GAA CGU GUC ACG U-3’) was 86 
purchased from Sigma (Wicklow, Ireland). The same sequence modified with 6FAM on the 87 
3’ end of the sense strand was used for fluorescence experiments (Sigma, Wicklow, Ireland). 88 
RelA siRNA (sense strand sequence 5’-CCAUCAACUAUGAUGAGUU-3’) was purchased 89 
from IDT (Coralville, Iowa, U.S.A.). Purified H2O (resistivity ≈ 18.2 MΩ cm) was used as a 90 
solvent for the synthesis of AuNPs. All glassware was cleaned with aqua regia (3 parts of 91 
concentrated HCl and 1 part of concentrated HNO3), rinsed with distilled water, ethanol and 92 
acetone, and oven-dried before use.  93 
2.2 Synthesis of AuNPs 94 
2.2.1 UV-visible Spectroscopy 95 
Optical absorption spectra were obtained on a CARY UV−visible spectrophotometer with a 96 
Xenon lamp (190−900 nm range, 0.5 nm resolution). 97 
2.2.2 Scanning Electron Microscopy (SEM) 98 
AuNPs were deposited from solution onto a Si wafer and air-dried prior to analysis using a 99 
FEI 630 NanoSEM equipped with an Oxford INCA energy dispersive X-ray (EDX) detector 100 
operated at 5 kV. 101 
2.2.3 Attenuated-Total-Reflection Infrared Spectroscopy (ATR-IR) 102 
 103 
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ATR-IR spectra were collected on a Nicolet 6700 Infrared Spectrometer equipped with a 104 
VariGATR (Harrick Scientific) and a liquid N2 cooled MgCdTe (MCT) detector. The 105 
samples were mounted on a KBr disc and spectra were collected under p-polarization at a 106 
grazing angle of 65 ° using 1000 cumulative scans with a resolution of 2 cm-1. 107 
2.2.4 NMR 108 
1H (600 MHz) and 13C (150.9 MHz) NMR spectra were recorded on a Bruker Avance III 600 109 
NMR spectrometer using a Bruker 5mm Dual C-H Cryoprobe operating at 17 K with a 110 
sample temperature of 300 K. All spectra were recorded in deuterated dimethylsulfoxide 111 
(DMSO-d6) using trimethylsilylpropanoic acid (TSP) as an internal chemical shift reference 112 
standard. 113 
2.2.5 Synthesis of Gold Nanoparticles Capped with PEI 114 
1 ml PEI (2.3 mmol L-1) was added to 203 ml of HAuCl4.3H2O (0.25 mmol L-1) under 115 
stirring at room temperature (RT); the colour of the solution changed from pale yellow to 116 
deep yellow. On addition of 0.71 ml of L-ascorbic acid (100 mmol L-1) the colour of the 117 
solution turned red within 5 s. The solution was kept under stirring at RT overnight to obtain 118 
Au-PEI NPs. 119 
2.2.6 Synthesis of NHS-activated Anisic Acid 120 
EDC.HCl (1.5 eq, 1.9 g, 9.9 mmol) was added to a solution of anisic acid (1 g, 6.572 mmol) 121 
in dry DCM (250 ml) under Argon, followed by N-hydroxysuccinimide (NHS) (1.45 eq, 1.1 122 
g, 9.56 mmol). The reaction mixture was stirred for approximately 42 h under Argon at RT. 123 
The organic phase was washed twice with water followed by a wash with brine, dried over 124 
magnesium sulfate (MgSO4), filtered on whatman filter paper and evaporated. The activated 125 
ester thus obtained was left to stir in 30 ml dry pentane for approximately 48 h. It was 126 
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filtered, dried under vacuum and used without further purification. The anisic-NHS ester 127 
yield was approximately 90 %. The product was analysed using FTIR and NMR 128 
spectroscopy. 129 
2.2.7 Synthesis of Anisamide-targeted Gold Nanoparticles (Au-PEI-AA) 130 
250 µl of NaOH 0.1 M was added to 25 ml of pre-synthesized ~ 60 nm Au-PEI NPs (~ 0.25 131 
mmol L-1-11.2 µmol L-1), followed by the addition of 0.5 ml of anisic-NHS (25 mg/ml) in dry 132 
DMSO and the solution was left under stirring for 21 h at RT to achieve Au-PEI-AA NPs. 133 
The resulting Au-PEI-AA solution was purified using centrifugation at 12,000 rpm for 15 134 
min and the free anisic-NHS in the supernatant was quantified using a CARY UV-Vis 135 
spectrophotometer with a Xenon lamp (190-900 nm range, 0.5 nm resolution). 136 
2.3 Cell Culture 137 
PC3 human prostate cancer cells (European Collection of Cell Cultures (ECACC)) were 138 
cultured in RPMI-1640 media supplemented with 10 % Fetal Bovine Serum (FBS), 2 mM L-139 
Glutamine, 50 units/ml penicillin and 50 µg/ml streptomycin 17. Cells were maintained in a 140 
humidified, 5 % CO2 tissue culture incubator at 37 ºC. 141 
2.4 Preparation of Gold:siRNA Complexes 142 
To complex siRNA, Au-PEI and Au-PEI-AA were mixed at the required Au:siRNA mass 143 
ratio (MR) in water and incubated at RT for 30 min at 300 rpm on a thermomixer. 144 
2.5 Gel Retardation Assay 145 
The ability of AuNPs to complex siRNA was assessed using gel retardation 15. 146 
Nanocomplexes were prepared at various MRs of Au:siRNA up to MR 10. Samples were 147 
then mixed with 1x Blue Juice Gel loading buffer (Invitrogen, U.S.A.) and loaded onto a 1 % 148 
(w/v) agarose gel containing SafeViewTM (NBS Biologicals Ltd, England) (6 µl/100 ml). 149 
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Each well contained 0.5 µg siRNA and naked siRNA (uncomplexed by AuNPs) was used as 150 
a control. Electrophoresis was carried out at 120 V for 30 min with a Tris-borate-EDTA 151 
buffer. The resulting gel was photographed under UV light. 152 
2.6 Size and Charge Measurements 153 
Particle Z-average size and charge were measured using dynamic light scattering (DLS) and 154 
electrophoretic mobility measurements respectively using the Malvern Zetasizer Nano ZS 15. 155 
AuNP.siRNA complexes were prepared at MR 7.5 (as detailed in section 2.4) to a final 156 
volume of 1 ml. Each sample contained 20 µg gold. Three readings of Z-average size (nm), 157 
polydispersity and zeta potential (mV) were taken at 25ºC using the default non-invasive 158 
back scattering (NIBS) technique with a detection angle of 173 °. 159 
2.7 Competitive Uptake 160 
To investigate if cellular uptake of the nanocomplexes was mediated via binding of the 161 
anisamide moiety to the sigma receptor, competitive uptake following pre-incubation with 162 
haloperidol was undertaken 5. PC3 cells were seeded 1 x 105 cells/well in 24-well plates 24 h 163 
prior to transfection. Before transfection, cells were pre-treated with 50 µM haloperidol for 3 164 
h. Control cells were incubated with fresh media without haloperidol. Au-PEI and Au-PEI-165 
AA were complexed with fluorescent siRNA at MR 7.5. Complexes (final volume 125 166 
µl/well in water) were added to cells in serum-free and antibiotic-free media (375 µl/well). 167 
Control cells were incubated in 375 µl transfection media and 125 µl water. Naked siRNA 168 
samples were prepared by diluting siRNA to 125 µl/well in water and were added to 375 µl 169 
transfection media. Fluorescent siRNA complexed with Lipofectamine 2000 ® (Invitrogen) 170 
was prepared as per manufacturer’s instruction. Transfection was carried out over 4 h using 171 
50 nM siRNA. After this time period, cells were incubated with 200 µl CellScrubTM 172 
(Genlatins) for 15 min to remove uninternalised complexes from the cell surface 6. They were 173 
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then washed twice with pre-warmed PBS and detached from plates using 200 µl 0.25x 174 
Trypsin (15 min, 37ºC). Cells were centrifuged at 1000 rpm for 5 min (4 °C) and washed 175 
with 1 ml cold PBS. They were centrifuged again at 1000 rpm for 5 min (4 °C) and 176 
resuspended in 700 µl cold PBS in Polystyrene Round-Bottom Tubes (Becton 177 
Dickinson).The fluorescence associated with 10,000 cells was measured with a FACS Caliber 178 
instrument (BD Bioscience) and the data was analysed using the Cell Quest Pro software.  179 
2.8 Intracellular Fate of Targeted AuNPs 180 
To investigate the time course of Au-PEI-AA.siRNA uptake and intracellular distribution, co-181 
localisation with the endolysosomal compartment was investigated 30 min and 4 h post-182 
transfection 5. PC3 prostate cancer cells were seeded 5 x 104 cells/well in 12-well culture 183 
plates with glass bottoms (MatTekTM). After 48 h, Au-PEI-AA was complexed with siRNA at 184 
MR 7.5. Cells were transfected with 100 nM fluorescent siRNA for 30 min or 4 h in serum-185 
free media. At the end of the transfection period, late endosomes and lysosomes were labelled 186 
using 75 nM LysoTracker Deep Red (Molecular Probes, Invitrogen) in RPMI-1640 for 30 187 
min at 37 °C. Cells were washed with PBS and analysed using an Olympus FV 1000 confocal 188 
microscope. Fluorescent siRNA was detected using excitation at 488 nm and LysoTracker 189 
Deep Red was detected using excitation at 633 nm. 190 
2.9 Toxicity of AuNPs 191 
Cytotoxicity of AuNP.siRNA complexes was assessed using the MTT assay with 3-(4, 5-192 
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide 18. PC3 prostate cancer cells were 193 
seeded 1 x104 cells/well 24 h prior to transfection in 96-well plates. siRNA (200 nM) or 194 
AuNP.siRNA complexes were added to cells in both serum-containing and serum-free media 195 
for 24 h. siRNA complexed with Lipofectamine 2000 ® was prepared as per manufacturer’s 196 
instructions. After 24 h, the media was replaced with 100 µl RPMI-1640 and 20 µl MTT (5 197 
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ml/ml solution in PBS) and incubated at 37 °C for 4 h. The supernatant was removed and the 198 
formazon crystals were dissolved in 100 µl DMSO. Absorbance was measured at 570 nm 199 
using a UV plate reader.  200 
2.10 Gene Knockdown 201 
The RelA unit of Nuclear Factor κB (NF-κB) was selected as a prostate cancer-relevant gene 202 
for gene knockdown experiments 3. PC3 cells were seeded 5 x 104 cells/well in 24 well plates 203 
24 h prior to transfection. AuNPs were complexed with negative control non-silencing 204 
siRNA or RelA siRNA at MR 7.5. Lipofectamine 2000 ® formulations were prepared as per 205 
manufacturer’s instructions. Transfection was carried out over 24 h using 200 nM siRNA in 206 
both serum-containing and serum-free media. At the end of the transfection period, cells were 207 
lysed and RNA was extracted using GenEluteTM Mammalian Total RNA Miniprep Kit 208 
(Sigma) as per manufacturer’s instructions. First-strand complementary DNA (cDNA) was 209 
generated from the total RNA using a High Capacity cDNA Reverse Transcription Kit 210 
(Applied Biosystems). Gene expression was assessed by real-time qPCR using the Applied 211 
Biosystem’s Real Time PCR System (Model 7300). Cycling conditions were as follows: 10 212 
min (min) at 95 °C, 40 cycles of [15 s (sec) at 95 °C; 1 min at 60 °C]. Assays were performed 213 
using appropriate primer sets for RelA (catalogue number Hs01042010_m1) and 18S 214 
(catalogue number Hs99999901_s1) (Taqman ®, Applied Biosystems). The quantitative level 215 
of each RelA mRNA was measured as a fluorescent signal corrected according to the signal 216 
for 18S mRNA. The 2-delta Ct method was used to quantify the relative changes in mRNA 217 
19. 218 
2.11 Cellular Uptake in Absence/Presence of Serum 219 
Both flow cytometry and fluorescent microscopy were used to assess nanoparticle uptake in 220 
the absence and presence of serum proteins. 221 
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For flow cytometry analysis, PC3 cells were seeded 1 x 105 cells/well in 24-well plates 24 h 222 
prior to transfection. AuNPs were complexed with fluorescent FAM-siRNA at MR 7.5. 223 
Complexes were added to cells as detailed in section 2.7.  Transfection was carried out over 224 
24 h using 50 nM siRNA and samples were prepared for flow cytometry analysis as 225 
previously outlined in section 2.7. The fluorescence associated with 10,000 cells was 226 
measured with a FACS Caliber instrument (BD Bioscience) and the data was analysed using 227 
the Cell Quest Pro software.  228 
In addition, for microscopy analysis PC3 cells were seeded 1 x 105 cells/well 24 h prior to 229 
transfection. AuNPs complexed with FAM-siRNA at MR 7.5 were added to cells. 230 
Transfection was carried out over 4 h using 100 nM siRNA in both serum-containing and 231 
serum-free media. After this time period, cells were incubated for 15 mins with CellScrubTM 232 
and washed twice with PBS. Samples were imaged in PBS using an Olympus IX70 inverted 233 
microscope (exciter filter BP470-490, barrier filter BA515). 234 
2.12 Serum Stability 235 
In order to investigate the stability of siRNA alone and in complexation with AuNPs, siRNA 236 
(0.5 µg) or AuNP.siRNA complexes were incubated for different time intervals in 10 % (v/v) 237 
FBS at 37 ºC 20. Following incubation at 4, 8 and 24 h, the serum was inactivated by heating 238 
the sample to 80 °C for 5 min. Samples were then stored at -20 ºC until ready for analysis by 239 
gel electrophoresis. Samples included at time 0 were prepared with 10% FBS which was 240 
previously heat deactivated by heating at 80 °C for 5 mins. All samples were then treated 241 
with excess heparin (2000 I.U./ml in PBS) for 1 h at RT. Samples were mixed with 1x Blue 242 
Juice Gel loading buffer and loaded onto a 1.5 % (w/v) agarose gel containing SafeViewTM (6 243 
µl/100 ml). Electrophoresis was carried out at 120 V for 30 min with a Tris-borate-EDTA 244 
buffer. The resulting gel was photographed under UV light. 245 
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In addition, the effect of serum on the particle size of AuNPs was investigated by incubating 246 
AuNPs in 10 % FBS for 4 h at 37 °C 18. Following this, size measurements were carried out 247 
by DLS. Each 1ml sample contained 20 µg gold. 248 
2.13 Statistical Analysis 249 
One-way analysis of variance (ANOVA) was used to compare multiple groups followed by 250 
Bonferroni’s post hoc test. In Figure 5 and Figure 10 two-way ANOVA was used to 251 
compare treatment groups followed by Bonferroni’s post hoc test. Statistical significance is 252 
displayed as *P<0.05, **P<0.01, ***P<0.001. 253 
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3 Results/Discussion 254 
3.1 Anisamide-targeted AuNPs 255 
As gene delivery vectors AuNPs have a number of advantages including good 256 
biocompatibility and ease of synthesis 21. In this study, gold nanospheres were used as a 257 
scaffold to prepare an anisamide-targeted siRNA delivery vector for use in prostate cancer 258 
(Figure 1). Firstly, AuNPs were chemically modified with PEI during the synthesis (Au-259 
PEI). PEI was used because it is a cationic polymer that is known for its capacity to complex 260 
negatively charged siRNA molecules. Furthermore, after nanoparticulate endocytosis, the pH 261 
of the endosome falls and PEI becomes protonated resulting in increased osmotic pressure in 262 
the endosome. This facilitates osmotic swelling, endosomal rupture and release of siRNA into 263 
the cytoplasm where it can exert it’s effect 22. The gold core was specifically modified with 264 
low molecular weight (MW) PEI (2kDa). Higher MW PEIs (e.g. 10 kDa, 70 kDa) are known to 265 
give better transfection rates 23 but cannot be metabolised by cellular enzymes and therefore 266 
are more toxic 24. In addition, strong binding of high MW PEIs to nucleic acids can result in 267 
poor intracellular release and reduced efficiency 24. In this study, the purpose of the PEI was 268 
to facilitate siRNA binding to the gold nanoparticle and subsequent intracellular release. 269 
Hence, non-toxic low MW PEI was used. The Au-PEI nanoparticle was conjugated directly 270 
with pre-activated anisamide (Anisic-NHS ester) to prepare an anisamide-targeted AuNP 271 
(Au-PEI-AA). The targeting ligand anisamide is known to bind specifically to the sigma 272 
receptor which is over-expressed on the surface of prostate cancer cells 5, 25. The untargeted 273 
control was prepared in the same way but without the conjugation of anisamide (Au-PEI) 274 
(Figure 1). 275 
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3.2 Synthesis and Characterization of Au-PEI 276 
Most studies using PEI capped gold nanoparticles (Au-PEI) utilise a slow (at RT) or a fast 277 
(high temperature) auto reduction of HAuCl4.3H2O by addition of excess PEI (used 278 
simultaneously as reductant and stabilizer) 16, 26, 27. In this study, a simple and direct reduction 279 
of HAuCl4.3H2O precursor in the presence of PEI (2 kDa) with ascorbic acid at RT was used 280 
to synthesise Au-PEI NPs 28. On addition of a small amount of PEI to HAuCl4  the colour of 281 
the solution changed from light to deep yellow indicating the formation of a complex 282 
between the amino groups of the PEI and the Au metal ions. The addition of ascorbic acid 283 
 
Figure 1 
Schematic showing the untargeted (Au-PEI) and targeted (Au-PEI-AA) AuNPs. The AuNP 
core was first coated with cationic PEI during its synthesis. The PEI was then chemically 
conjugated with anisamide and complexed with siRNA to form the targeted Au-PEI-AA 
nanoparticle. The untargeted counterpart (Au-PEI) was prepared in the same way but without 
the conjugation with anisamide on the cationic PEI surface. 
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reduced the Au ions into Au (0) and the PEI capped Au-PEI NPs formed quickly (within 5 284 
seconds) as indicated by the change in colour of the solution to red 15, 29, 30. The UV-Vis 285 
spectrum showed that the resulting nanoparticles possessed an absorption band with a 286 
wavelength centred at approximately 534 nm (Figure 2 (a)) due to the surface plasmon 287 
resonance band of AuNPs. SEM analysis showed the nanoparticles were spherical in shape 288 
with an average gold core diameter of about 52 ± 8 nm as analysed using Image J software 289 
(Figure 2(b) and (c)). However, the overall average size of the nanoparticle dispersion 290 
obtained from DLS measurements in water was slightly larger (Z-average size 67 ± 2 nm, 291 
polydispersity index (PDI) 0.12 ± 0.01), with a positive Zeta Potential (31 ± 1 mV) (Table 1). 292 
This confirmed that AuNPs were successfully coated with PEI. It is worth noting that the Au-293 
PEI NP was stable for more than two month at 4 °C.  294 
 
Figure 2 
(a) UV-vis spectrum of the obtained Au-PEI NPs; (b) SEM image of Au-PEI (scale bar = 500 
nm); (c) size of Au-PEI (52 ± 8 nm) analysed from SEM images using Image J 
software(more than 500 nanoparticles were counted and their size was determined). 
3.3 Synthesis and Characterisation of Anisamide-targeted Au-PEI-AA 295 
The anisic acid was activated by reacting with NHS to form an anisic-NHS ester which could 296 
react with the amino groups of PEI in water to form a stable amide linkage. This resulted in 297 
the formation of Au-PEI-AA NPs. The successful activation of the anisic acid was confirmed 298 
with FTIR and NMR analysis as presented in supporting information. Figure S1 shows the 299 
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ATR-FTIR spectrum of the anisic acid, NHS and anisic-NHS product. It is evident from this 300 
spectrum that the product is very different from the starting material with shifted bands 301 
supporting its formation. The purity (~ 95 %) and formation of the product anisic-NHS was 302 
also confirmed by 1H and 13C NMR analysis (Results not shown). 303 
The synthesis of AuNPs-PEI-AA (Figure 1) was adapted from a method previously 304 
described by Xu et al 31 where fluorescein was attached onto gadolinium oxide NPs capped 305 
with PEI. In this study the amines of PEI were reacted with NHS-activated anisic acid. The 306 
attachment of anisic acid-NHS onto the Au-PEI surface did not show a significant change in 307 
the initial red colour of the gold solution nor the average size distribution, while the zeta 308 
potential was found to decrease slightly by ~ 5 mV (p < 0.01) after attachment of AA (Table 309 
1). To confirm the attachment of anisic acid onto Au-PEI NPs, UV-vis spectroscopy was 310 
used. The nanoparticles were collected by centrifugation and redispersed in water. The UV-311 
vis spectrum (Figure 3) showed a band at ~ 265 nm for Au-PEI-AA NPs. Furthermore, UV-312 
vis allowed us to quantify the anisic acid-NHS left in solution after centrifugation of the Au-313 
PEI-AA NPs. Results indicated that ~ 50 % (~ 35 µmol L-1) of the initially added anisic acid 314 
was grafted onto the Au-PEI surface as shown (Figure S2).  315 
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Figure 3 
UV-vis spectra of the obtained Au-PEI and Au-PEI-AA after purification (centrifugation and 
redispersion in water) diluted 5 times and adjusted to the same Amax . 
 316 
3.4 Agarose Gel Binding and Physicochemical Characterisation 317 
Cationic delivery vectors complex siRNA via electrostatic interaction with negatively 318 
charged phosphates on the siRNA backbone 32. The ability of Au-PEI and Au-PEI-AA to 319 
complex siRNA at different MRs was monitored by gel retardation. As show in Figure 4, the 320 
untargeted Au-PEI fully complexed siRNA even at the lowest MR tested. In contrast, the 321 
targeted Au-PEI-AA did not fully complex siRNA until MR 7.5. For Au-PEI-AA, the 322 
conjugation of PEI with the anisamide-targeting moiety caused some degree of steric 323 
interference significantly reducing the siRNA binding capacity. Hence a higher MR of 324 
Au:siRNA was required to fully complex siRNA. Thus in further studies, a constant MR 7.5 325 
of Au:siRNA was used for both untargeted and targeted nanoparticles. 326 
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Figure 4 
Binding gel of untargeted (Au-PEI) and targeted (Au-PEI-AA) AuNPs (MR = mass ratio 
Au:siRNA). Full complexation was evident for the Au-PEI at all mass ratios tested. Full 
complexation occurred at MR 7.5 for Au-PEI-AA. 
 327 
Particle size and surface charge are key parameters that affect the in vivo efficacy of 328 
nanoparticles for gene delivery. DLS was used to assess the size of Au-PEI and Au-PEI-AA 329 
both prior to and after complexation with siRNA. As shown in Table 1 nanoparticle diameter 330 
was unaffected by the addition of siRNA to the formulation (both Au-PEI and Au-PEI-AA). 331 
Au-PEI-AA had a slightly lower particle diameter (Au-PEI-AA 62.8 nm versus Au-PEI 69.8 332 
nm) possibly due to tighter packing of the PEI caused by the hydrophobic nature of the 333 
anisamide-targeting moiety. However, both AuNPs were within a suitable size range for 334 
exploiting the ‘enhanced permeability and retention (EPR) effect’ for passively targeting the 335 
‘leaky’ vasculature of solid tumours 33.  336 
 
Table 1 
Average nanoparticle size (nm), charge (mV) and polydispersity index (PDI) of untargeted 
(Au-PEI) and targeted (Au-PEI-AA) nanoparticles. Samples were prepared to contain 20 μg 
gold at a mass ratio Au:siRNA of 7.5 and measured in water at 25 °C. (n=3, mean ± S.D.). 
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The targeted nanoparticle had a slightly lower surface charge relative to the untargeted 337 
nanoparticle (+27.6 mV versus +33.8 mV) possibly due to the conjugation of free PEI amines 338 
to create the anisamide-targeting moiety. There was a trend toward reduced surface charge 339 
following complexation with siRNA by ~2.5-3 mV for both the untargeted and targeted 340 
nanoparticles due to charge neutralisation by anionic siRNA. Furthermore, the polydispersity 341 
index (PDI), which gives an indication as to the uniformity of nanoparticle size, was below 342 
0.4 for all samples indicating only a small variation in nanoparticle diameter 34. 343 
3.5 Prostate Cancer Cellular Uptake 344 
Recently, a variety of anisamide-targeted delivery vectors have been developed to 345 
specifically target the sigma receptor that is known to be over-expressed on the surface of 346 
prostate cancer cells 5, 25, 35. To investigate if the anisamide-targeted AuNPs facilitates siRNA 347 
uptake into prostate cancer cells, the sigma receptor positive prostate cancer PC3 cell line 348 
was used 5. Haloperidol, a known sigma receptor antagonist, is known to competitively 349 
inhibit anisamide-mediated uptake into sigma receptor positive cells 5, 25, 36 and was used to 350 
investigate receptor-mediated uptake. As shown in Figure 5, despite a high cationic surface 351 
charge, the untargeted Au-PEI nanoparticle had poor uptake into prostate cancer cells with or 352 
without haloperidol pre-treatment further reinforcing the poor ability of low MW PEI to 353 
mediate cell transfection 23. In contrast, the targeted Au-PEI-AA nanoparticle resulted in a 354 
high percentage of fluorescent-positive cells indicating successful transfection. As the only 355 
difference between the untargeted and targeted nanoparticle was the presence of the 356 
anisamide moiety, the high level of uptake gave a strong indication that the targeted 357 
nanoparticle was taken into cells via receptor-mediated endocytosis by binding to the sigma 358 
receptor. This uptake mechanism was confirmed by the finding that cellular siRNA uptake 359 
was significantly reduced following haloperidol pre-treatment of cells (P<0.001) (Figure 5) 5. 360 
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3.6 Intracellular Fate 361 
PEI is known to be highly efficient in facilitating endosomal escape after cellular uptake by a 362 
process termed the ‘proton sponge effect’ whereby the fall in pH in the endosome protonates 363 
PEI leading to increased osmotic pressure and endosomal rupture 37. In order to visualise the 364 
intracellular trafficking of FAM-labelled siRNA with Au-PEI-AA, the endosome was 365 
labelled using LysoTracker Deep Red. Cells were visualised at 30 min and 4 h to determine 366 
the subcellular location of siRNA at these time points. 367 
 
 
Figure 5 
AuNP cellular uptake into sigma receptor-positive PC3 prostate cancer cells. Transfection to 
investigate competitive uptake of AuNPs was carried out following 3 h pre-incubation with 
50 μM haloperidol. Cells were then incubated with Au-PEI and Au-PEI-AA complexed with 
FAM-siRNA (50 nM) for 4 h and cell uptake was measured using flow cytometry (n=3, mean 
± S.D.). (***P<0.001). 
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Figure 6 
Uptake of Au-PEI-AA complexed with FAM-siRNA into PC3 prostate cancer cells at 30 min 
and 4 h. (a) Confocal microscopy images demonstrating the intracellular fate following 
nanoparticle uptake. Left to right: FAM-siRNA, LysoTracker Deep Red, merged fluorescent 
images and merged fluorescent images including transmission. Green arrow indicates specific 
cells that were further magnified in (b). (b) Magnification of selective cells demonstrating 
subcellular location 30 min and 4 h post-transfection. Yellow arrow indicates co-localisation 
of siRNA with endosome. siRNA was fluorescently labelled (green) and the endosome was 
labelled using LysoTracker (red).  
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30 min after transfection there was little FAM-siRNA cellular uptake as demonstrated by the 368 
low level of green fluorescence visible within cells (Figure 6 (a)). However, when one of the 369 
siRNA-fluorescent-positive cells was magnified at this time point it was apparent that the 370 
formulation facilitated highly efficient endosomal escape (Figure 6 (b)).Even at this early 371 
time point some green fluorescent siRNA was visible in the cytoplasm of the cell following 372 
escape from the endosomal compartment. However, some fluorescent siRNA was also visible 373 
in the endolysosomes of the cell as apparent from the yellow staining resulting from the co-374 
localisation between the siRNA and LysoTracker Deep Red (yellow arrow, Figure 6(b)).  375 
At 4 h after transfection, much higher levels of siRNA are visible within the cell (Figure 6 376 
(a)) consistent with high cellular uptake of the targeted nanoparticle. At this time point the 377 
majority of siRNA had escaped from the endosome and was detected in the cytoplasm where 378 
it can exert its mechanism of action (Figure 6 (b)) 27. 379 
3.7 Cytotoxicity 380 
 
 
Figure 7 
PC3 prostate cancer cell viability 24 h post-transfection with complexes at MR 7.5 of 
Au:siRNA (200 nM siRNA) in the presence and absence of serum. Cell viability was 
measured using the MTT assay and absorbance values were normalised to the untreated 
control (n=3, mean ± S.D.). (* P < 0.05, ** P < 0.01 reduction in cell viability relative to 
untreated control). 
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AuNPs are generally recognised as non-toxic delivery vectors 38. However, the modification 381 
of AuNPs with PEI can result in increased cell toxicity, reportedly due to the presence of 382 
unbound cationic PEI in the aqueous solution which elicits more cell toxicity 27. Furthermore, 383 
a cationic surface charge on AuNPs, as is present on both Au-PEI and Au-PEI-AA 384 
formulations used in this study, may impact upon cellular toxicity 39, 40. It is essential that 385 
delivery vectors for siRNA gene therapy in cancer are non-toxic to cancerous cells. In 386 
contrast the toxicity should come from the RNAi effects of the siRNA and not from the 387 
nanocarrier itself 41. Hence the MTT assay was used to assess the impact of Au-PEI and Au-388 
PEI-AA formulations on cell toxicity. Serum is frequently included in cell culture media as it 389 
provides essential growth factors and hormones to facilitate cell growth 42. It also acts as a 390 
detoxification agent 42 whereby serum proteins bind to the nanoparticle surface and shield 391 
cells from the toxic surface coating 43. Hence the cytotoxicity of AuNPs both in the presence 392 
and absence of serum was investigated. 393 
Both Au-PEI and Au-PEI-AA nanoparticles proved to be non-toxic using 200 nM siRNA 394 
(Figure 7) at 24 h both in the presence and absence of serum. In contrast, the commercially-395 
available cationic lipid vector Lipofectamine 2000 ® significantly reduced cell viability in 396 
both the presence (P<0.05) and absence (P<0.01) of serum. Thus these AuNPs are suitable 397 
for investigating therapeutic gene knockdown in the PC3 prostate cancer cell line. 398 
3.8 Gene Knockdown 399 
In order to investigate the gene knockdown potential of both Au-PEI and Au-PEI-AA 400 
formulations in the presence and absence of serum, AuNPs were complexed with siRNA 401 
targeting the RelA subunit of the NF-κB transcription factor 44. The constitutive activation of 402 
this transcription factor is implicated in a variety of cancer types, including prostate cancer, 403 
where it leads to the transcription of a diverse range of genes including those associated with 404 
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proliferation, metastases and angiogenesis 3. Having established the nanoparticles were non-405 
toxic at 24 h using 200 nM siRNA, this time point and siRNA concentration were used to 406 
investigate gene knockdown. 407 
 
 
Figure 8 
Gene knockdown using AuNPs. (a) In serum-containing media. (b) In serum-free media. 
Knockdown of the RelA gene was quantified 24 h post-transfection with 200 nM siRNA. 
Negative control non-silencing siRNA was used as a control. (n=3, mean ± S.D.) 
(***P<0.001 relative to untreated control). 
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As demonstrated in Figure 8 (a), both the untargeted and targeted nanoparticles were unable 408 
to mediate RelA gene knockdown in serum-containing media. In contrast, the targeted 409 
nanoparticle mediated highly significant gene knockdown (~ 70 %) in serum-free transfection 410 
conditions (Figure 8 (b)) (P<0.001). Although the commercially available vector 411 
Lipofectamine mediated higher levels of gene knockdown relative to Au-PEI-AA in the 412 
absence of serum, it was toxic to cells and would be unsuitable as a gene delivery vector in 413 
vivo (Figure 7). The difference in gene knockdown mediated by Au-PEI-AA in the presence 414 
and absence of serum was then further investigated. 415 
3.9 Nanoparticle Uptake in the Absence and Presence of Serum 416 
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The uptake of fluorescent siRNA complexed with Au-PEI-AA was investigated using flow 417 
cytometry in the absence and presence of serum. As show in Figure 9 (a), uptake of Au-PEI-418 
AA was significantly reduced in the presence of serum. This result indicates that the lack of 419 
transfection by the targeted nanoparticle as shown in Figure 8 (a) was indeed the result of 420 
poor siRNA cellular uptake in the presence of serum. 421 
This result was further corroborated using fluorescent microscopy whereby PC3 cells were 422 
imaged 4 h post-transfection with fluorescent siRNA in the absence and presence of serum 423 
(Figure 9 (b)). Au-PEI had poor cellular uptake which was unaffected by the presence of 424 
serum. In contrast and similar to the results displayed in Figure 9 (a), the uptake of 425 
fluorescent siRNA complexed with Au-PEI-AA was reduced in serum-containing 426 
transfection conditions (P<0.001). 427 
Thus having established that serum proteins inhibited siRNA uptake when complexed with 428 
the targeted nanoparticle, two possible explanations were possible; (a) serum proteins may 429 
have displaced siRNA from the surface of AuNPs resulting in poor cellular uptake, or (b) 430 
binding of serum proteins to the targeted nanoparticle complexed with siRNA may have 431 
shielded the anisamide-targeting moiety on the surface of AuNPs thus inhibiting the receptor-432 
targeting ability of the formulation. In order to identify the most likely mechanism the serum 433 
stability of the nanoparticles was investigated. 434 
Figure 9 
AuNP cellular uptake into PC3 prostate cancer cells in the absence and presence of serum. (a) 
24 h uptake of 50 nM FAM-siRNA complexed with Au-PEI-AA as measured by flow 
cytometry (n=3, mean ± S.D.). (b) 4 h uptake of 100 nM FAM-siRNA complexed with Au-
PEI and Au-PEI-AA visualised by microscopy. (***P<0.001). 
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3.10 Serum Stability 435 
 
 
Figure 10 
AuNP stability in serum. (a)  Serum stability of siRNA following up to 24 h incubation in 10 
% FBS (naked or complexed with Au-PEI or Au-PEI-AA). (b) Particle size measurements of 
Au-PEI after incubation for 4 h in water or 10% serum. (c) Particle size measurements of Au-
PEI-AA after incubation for 4 h in water or 10% serum. 
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The stability of siRNA complexed with Au-PEI and Au-PEI-AA in 10 % FBS was 436 
investigated as previously employed using gel retardation after incubation at 37 °C for 24 h 437 
20. The results demonstrated that both Au-PEI and Au-PEI-AA protected siRNA from serum-438 
induced degradation for up to 24 h (Figure 10(a)). This result not only indicates that the 439 
nanoparticles were successful in protecting siRNA from degradation, but it also indicates that 440 
serum proteins do not displace siRNA from the surface of the nanoparticles. If displacement 441 
occurred, the siRNA would most likely be degraded by serum nucleases as occurred for 442 
naked siRNA (Figure 10 (a)).  443 
It is widely reported that negatively charged serum proteins in FBS can adsorb onto the 444 
cationic surface of nanoparticles 43, 45. To confirm this interaction occurs with the AuNPs in 445 
this study, particle size was measured in water and in 10 % serum following incubation at 37 446 
°C for 4 h. The particle diameters of both Au-PEI (Figure 10 (a)), and Au-PEI-AA (Figure 447 
10 (b)) increased following incubation in FBS relative to water (average diameter untargeted 448 
213.9 nm versus 68.54 nm; targeted: 125.6 nm versus 66.5 nm). This increase in particle size 449 
is indicative of non-specific protein binding to the surface of the nanoparticle 34. Previously 450 
such interactions have been reported to improve the transfection efficacy of AuNPs 46. This 451 
has been attributed to the ability of adsorbed serum proteins to stabilise nanoparticles against 452 
aggregation in electrolytic solutions 43. However, it is evident in this study that the adsorption 453 
of serum proteins has the opposite effect on transfection by these nanoparticles. The 454 
anisamide-functionalised Au-PEI-AA nanoparticles appear to lose their targeting ability to 455 
access the sigma receptor on PC3 cells due to shielding of the ligand by adsorbed serum 456 
proteins. Hence further modification of the Au-PEI-AA is necessary to increase in vivo 457 
activity, where serum is present. The incorporation of poly(ethylene glycol) (PEG) chains 458 
into formulations have been widely reported to stabilise particles against nonspecific binding 459 
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of proteins 47. The option to modify the formulation of the AuNPs with PEG will be the focus 460 
of future work. 461 
4 Conclusion 462 
In conclusion an anisamide-targeted AuNP using low MW PEI to complex siRNA was 463 
successfully synthesised and tested in PC3 prostate cancer cells. Uptake of Au-PEI-464 
AA.siRNA was competitively reduced after pre-incubation with haloperidol proving that 465 
uptake occurred via binding to the sigma receptor. The PEI present in Au-PEI-AA mediated 466 
highly efficient endosomal escape. Both Au-PEI and Au-PEI-AA nanoparticles were non-467 
toxic up to 200 nM siRNA in the presence and absence of serum. Au-PEI-AA mediated 468 
highly efficient RelA gene knockdown but only in serum-free transfection conditions. While 469 
this is the first time that the anisamide-targeting moiety has been successfully utilised to 470 
target AuNPs to prostate cancer cells, further modification of the formulation is required to 471 
avoid interaction with serum proteins and thus to enhance the potential for in vivo 472 
application. 473 
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6 Supplementary Information 481 
 
Figure S1. ATR-IR spectra of the anisic acid, NHS and the obtained product activated anisic-
NHS Ester  
 482 
 
Figure S2. UV-vis absorption spectra of anisic –NHS. In order to verify that NHS activated 
anisic acid was attached onto Au-PEI, the resultant colloidal solution was centrifuged at 
12,000 rpm at RT for 15 min. The anisic-NHS in the supernatant (red) was analysed using 
32 
 
UV-visible spectroscopy. When compared to anisic-NHS prepared using a concentration of 
69 µM (blue, a concentration for the reaction initially), results indicated that more than 50% 
of anisic-NHS had been grafted onto Au-PEI. 
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